AR077410A1 - Metodo de cicatrizacion de heridas y modulacion de cicatrices - Google Patents

Metodo de cicatrizacion de heridas y modulacion de cicatrices

Info

Publication number
AR077410A1
AR077410A1 ARP100102522A ARP100102522A AR077410A1 AR 077410 A1 AR077410 A1 AR 077410A1 AR P100102522 A ARP100102522 A AR P100102522A AR P100102522 A ARP100102522 A AR P100102522A AR 077410 A1 AR077410 A1 AR 077410A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
dimethicone
cross polymer
scars
modulation
Prior art date
Application number
ARP100102522A
Other languages
English (en)
Spanish (es)
Inventor
Brian C Keller
Original Assignee
Crescendo Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescendo Therapeutics Llc filed Critical Crescendo Therapeutics Llc
Publication of AR077410A1 publication Critical patent/AR077410A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP100102522A 2009-07-09 2010-07-12 Metodo de cicatrizacion de heridas y modulacion de cicatrices AR077410A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22440809P 2009-07-09 2009-07-09
US22621609P 2009-07-16 2009-07-16

Publications (1)

Publication Number Publication Date
AR077410A1 true AR077410A1 (es) 2011-08-24

Family

ID=43427950

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102522A AR077410A1 (es) 2009-07-09 2010-07-12 Metodo de cicatrizacion de heridas y modulacion de cicatrices

Country Status (10)

Country Link
US (1) US20110009374A1 (https=)
EP (1) EP2451280A4 (https=)
JP (1) JP2012532889A (https=)
CN (1) CN102480969A (https=)
AR (1) AR077410A1 (https=)
AU (1) AU2010271205A1 (https=)
BR (1) BR112012001098A2 (https=)
CA (1) CA2767661A1 (https=)
MX (1) MX2012000434A (https=)
WO (1) WO2011006100A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322875A1 (en) 2009-06-18 2010-12-23 Advanced Bio-Technologies, Inc. Silicone scar treatment preparation
US8623040B2 (en) 2009-07-01 2014-01-07 Alcon Research, Ltd. Phacoemulsification hook tip
WO2012012390A1 (en) 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US10258505B2 (en) 2010-09-17 2019-04-16 Alcon Research, Ltd. Balanced phacoemulsification tip
ITMI20111050A1 (it) 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
CA2837526C (en) 2011-06-24 2019-07-09 Merz Pharma Gmbh & Co. Kgaa Composition comprising an onion extract and liposomes
US9364510B2 (en) 2011-07-19 2016-06-14 Marvphyt Development Llc Botanical composition and methods of manufacture and use
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
CN104080458B (zh) * 2011-09-13 2020-06-02 布莱阿姆青年大学 用于组织创伤的愈合的产品
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
GB201120724D0 (en) * 2011-12-01 2012-01-11 Gauthier Rene System and method for alleviating the appearance of scars and/or scar tissue
FR2985064B1 (fr) * 2011-12-23 2016-02-26 Oreal Procede pour delivrer un conseil cosmetique
EP2841106A1 (en) * 2012-04-27 2015-03-04 Dow Corning Corporation Topical formulation compositions containing silicone based excipients to deliver actives to a substrate
CA2872190C (en) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US9808654B2 (en) * 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014175861A1 (en) * 2013-04-23 2014-10-30 Hewlett-Packard Development Company, L.P. Recovering from compromised system boot code
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
WO2015099660A1 (en) * 2013-12-23 2015-07-02 Intel Corporation Integrated component interconnect
WO2015189712A2 (en) 2014-06-09 2015-12-17 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
MA40433A (fr) 2014-07-21 2017-06-14 Sevecom Spa Émulsion en poudre pour aliments pour animaux
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ 15-pgdh阻害剤とコルチコステロイドおよび/またはtnf阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN113453670A (zh) * 2018-09-28 2021-09-28 乔·斯图丁 类固醇和大分子的透孔递送
CN120463721A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
US20200397720A1 (en) * 2019-06-23 2020-12-24 Charles Huntington Gallina Method and formulation for treatment of wounds by new tissue regeneration with reduced trauma and scar tissue formation
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
US20240180812A1 (en) * 2022-07-27 2024-06-06 Bio Med Sciences, Inc. Method of improving outcomes of dermal tattoos and tattoo removal procedures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
KR100362924B1 (ko) * 2000-01-11 2002-11-30 주식회사 동구약품 외피용약제 조성물
WO2001089464A1 (en) * 2000-05-23 2001-11-29 Unilever Plc Deodorant and/or antiperspirant compositions
GB0018466D0 (en) * 2000-07-27 2000-09-13 Strakan Pharm Ltd Keloid Treatment
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
JP4450545B2 (ja) * 2001-07-05 2010-04-14 ロート製薬株式会社 エアゾール製剤
JP4549006B2 (ja) * 2002-05-07 2010-09-22 ロート製薬株式会社 ゲル軟膏
GB0216427D0 (en) * 2002-07-16 2002-08-21 Advanced Biotechnologies Inter Wound dressing
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
JP2008502647A (ja) * 2004-06-17 2008-01-31 ガルデルマ・ソシエテ・アノニム シリコーン剤、コルチコステロイドおよびビタミンdまたはその誘導体を含む乾癬治療用組成物
CN101247787B (zh) * 2005-06-10 2011-10-05 盖尔德玛公司 以包含药物、成膜聚硅氧烷和至少一种挥发性溶剂为基础的经皮药物的控制释放
MX2009009557A (es) * 2007-03-08 2010-08-10 Crescendo Therapeutics Llc Formulaciones de aposito para prevenir o reducir la cicatrizacion.
US20080317830A1 (en) * 2007-06-25 2008-12-25 Liolabs Llc Compositions and Methods for the Treatment of Wounds and Scar Tissue
DE102009030931A1 (de) * 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Chirurgisches Wundverschlusselement

Also Published As

Publication number Publication date
AU2010271205A1 (en) 2012-02-09
CA2767661A1 (en) 2011-01-13
US20110009374A1 (en) 2011-01-13
MX2012000434A (es) 2012-04-11
JP2012532889A (ja) 2012-12-20
EP2451280A1 (en) 2012-05-16
BR112012001098A2 (pt) 2015-09-01
CN102480969A (zh) 2012-05-30
WO2011006100A1 (en) 2011-01-13
EP2451280A4 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
AR077410A1 (es) Metodo de cicatrizacion de heridas y modulacion de cicatrices
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
JP2012532889A5 (https=)
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BRPI0507198A (pt) derivados de bisariluréia
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
Georgiev et al. Comparison of topical and intravenous administration of tranexamic acid for blood loss control during total joint replacement: Review of literature
BR112014010542A2 (pt) métodos e composições para tratamento de ferimento
MX2015017771A (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BRPI0923362B8 (pt) método de produção de uma composição de liberação controlada de fosfato de ácido ascórbico, composição de liberação controlada e dispositivo médico.
BR112014024793A2 (pt) método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica.
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
BR112013003847A2 (pt) métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
BR112014013682B8 (pt) composição para cuidado pessoal
BR112012032076A2 (pt) composição farmacêutica, e, métodos para tratar um paciente que está sofrendo de um distúrbio e de uma doença neurodegenerativa
CL2008001775A1 (es) Compuestos derivados de 2-amino-7-alquinil-[1,8]naftiridona, inhibidores de vegfr-3; composición farmacéutica; combinación farmacéutica; procedimiento de preparación; compuesto intermediario; y uso en el tratamiento del cáncer.
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
BR112012003907A2 (pt) composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês
BR112012017476A2 (pt) composto, composição, método para preparar uma composição, uso de um composto, e, métodos para tratar doenças, para inibir um alérgico peptidase do ácaro da poeira, para exterminar ácaros, para controlar uma população de ácaros

Legal Events

Date Code Title Description
FB Suspension of granting procedure